Schaffhausen, Switzerland (ots) - Schaffhausen Institute of Technology (SIT) launched SIT Programming School for Children Aged 6 to 13 to help children become the next generation of digital leaders. These days if you're looking to get yourself hired as a coder by international tech giants like Google, Facebook, or Microsoft, you need to start early. That's why SIT ...
Schaffhausen, Switzerland (ots) - The Schaffhausen Institute of Technology (SIT) launched the SIT Academy, an ambitious executive education program that combines Computer Science, Physics, and Business Studies. SIT Academy is built on the innovative SIT Alemira digital learning ecosystem to achieve a unique learning ...
DGAP-News: BB BIOTECH AG / Key word(s): Half Year Results BB Biotech shares hold steady in the second quarter (news with additional features) 20.07.2018 / 07:00 The issuer is solely responsible for the content of this announcement. Media release as of July 20, 2018 Interim report of BB Biotech AG as of June 30, 2018 BB Biotech shares hold steady in the second quarter - Substantial portfolio adjustments, new investments ...
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning/Half Year Results BB Biotech AG reports preliminary results for 1H 2018 12-Jul-2018 / 18:05 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 703867 12-Jul-2018 CET/CEST ...
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Miscellaneous BB Biotech AG admitted to the SMIM and SPI Index 09-Jul-2018 / 18:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 702815 09-Jul-2018 CET/CEST ...
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Quarter Results BB Biotech share gains value in first quarter 2018 - several large-cap biotech companies trading at well below fundamental value 20-Apr-2018 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, ...
DGAP-News: BB BIOTECH AG / Key word(s): AGM/EGM BB BIOTECH AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 3.30 13.03.2018 / 17:40 The issuer is solely responsible for the content of this announcement. 663703 13.03.2018 ...
DGAP-News: BB BIOTECH AG / Key word(s): Final Results BB Biotech AG publishes its 2017 annual report (news with additional features) 16.02.2018 / 07:00 The issuer is solely responsible for the content of this announcement. 654741 16.02.2018 ...
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning BB Biotech shows a double-digit total return for 2017 - mid caps overdeliver on innovation and are becoming a key upside trigger 19-Jan-2018 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS ...
DGAP-News: BB BIOTECH AG / Key word(s): Miscellaneous BB Biotech statement on MiFID II (news with additional features) 30.10.2017 / 17:40 The issuer is solely responsible for the content of this announcement. 623749 30.10.2017 ...
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): 9-month figures BB BIOTECH AG: Product approvals and solid company results lead the biotech sector higher 20-Oct-2017 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely ...
Schaffhausen/Zurich, Switzerland (ots) - Professional services provider Evalueserve welcomes Dr. Christian Casal and Armin Meier to its Board of Directors to strengthen its leadership team. Dr. Christian Casal is a former Director of McKinsey & Co. Inc. and Armin Meier is the owner and Managing Director of Boyden global executive search AG. Both executives bring to the Board extensive senior management and corporate governance experience from private and public companies ...
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Half Year Results BB BIOTECH AG: Tailwind for biotech investors 21-Jul-2017 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 594383 21-Jul-2017 CET/CEST ...
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Quarter Results BB Biotech reports pleasing quarterly results 21-Apr-2017 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 565879 21-Apr-2017 CET/CEST ...
DGAP-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend BB Biotech AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 2.75 (news with additional features) 16.03.2017 / 17:35 The issuer is solely responsible for the content of this announcement. ...
DGAP-News: BB BIOTECH AG / Key word(s): Final Results BB BIOTECH AG: Annual report 2016 (news with additional features) 17.02.2017 / 07:00 The issuer is solely responsible for the content of this announcement. 545123 17.02.2017 ...
DGAP-News: BB BIOTECH AG / Key word(s): Quarterly / Interim Statement BB Biotech weathers a challenging past year - portfolio performs well in in the volatile fourth quarter of 2016 (news with additional features) 20.01.2017 / 07:00 The issuer is solely responsible for the content of this announcement. ...
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning BB Biotech AG with loss in the business year 2016 13-Jan-2017 / 18:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 536365 13-Jan-2017 CET/CEST ...